Microgen, Adaptive Phage Therapeutics, Phagelux Inc., Are Dominating The Global Bacteriophages Therapy Market In 2020

Global Bacteriophages Therapy Market is expected to grow with a CAGR of 5.7% in the forecast period of 2021 to 2028. The years considered for the study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-bacteriophages-therapy-market

Global bacteriophages therapy market is a highly consolidated market, which includes a specific number of key players. The market has witnessed increased strategic developments owing to favorable market scenarios.   

The major players dealing in the global bacteriophages therapy market are introducing a strong range of products provider along with launching new products and adopting strategic initiatives such as acquisition, agreement, business expansion, award, and recognition into the market. This helped companies to maximize sales with an enhanced product portfolio.

For instance:

  • In October, Microgen announced that Russian Bacteriophages are used in the prevention of emergency infections. The company further added that over 3,000 products had been delivered to the Kuban. This has helped the company to earn more revenue.

Microgen is the dominating player in the global bacteriophages therapy market. The other key players existing in the market are Adaptive Phage Therapeutics, Phagelux Inc., Intralytix, Armata Pharmaceuticals Inc., Locus Biosciences Inc., Arthur Andrew Medical, NextBiotics, Pherecydes Pharma, Pylum, intoDeWorld Inc., Enbiotix, Theraphage, Cytophage Technologies Inc., Fixed-Phase Limited, MICREOS, among others.

Bacteriophages Therapy Market Microgen

Microgen headquarter is in Russia, Europe, founded in 2003. The company focuses on developing highly effective preparations for healthcare by creating competitive production units in the sphere of biotechnology. The company has wide product categories such as vaccines, allergens, anatoxins, toxins, bacteriophages, immunomodulators, interferons, blood products, sera, culture media, medical devices for diagnostics in vitro, other products, among others in which bacteriophages is the market-focused category. The company is attaining lucrative growth through several strategic initiatives.

For instance,

  • In April, Microgen announced that they had developed a universal drug product that permits one capsule to replace the intake of a complex of traditional antimicrobial agents for infectious diseases treatment. The drug attacks only bacterial cells without affecting the body flora. This has helped the company to enhance its reputation for quality and to reduce the cost of competitiveness

The company has a wide presence across Europe.

Adaptive Phage Therapeutics

Adaptive phage therapeutics was founded in 2016 in Maryland, the U.S. The company is focused on delivering phage therapy effectively and precisely. The company has wide product categories such as Phage Bank and PST (Phage Susceptibility Test), in which Phage Bank is the market-focused product. The company is attaining lucrative growth through several strategic initiatives.  

  • In June, Adaptive Phage Therapeutics announced the initiation of Phase 1/2 study of bacteriophage therapy (Phage Bank) to evaluate the safety, tolerability, and efficacy of targeted, personalized bacteriophage (“phage”) treatments in patients with urinary tract infection (UTI). This has helped the company to develop a novel treatment for multi-drug-resistant bacterial infections

The company has a wide presence across North America.

PhageLux Inc.,

Phagelux Inc. is headquartered in Shanghai, China, and was founded in 2013. The company is focused on providing solve bacterial problems in various fields. The company has various product categories that are spray, pro-patch and spray patch, hydrogel-eczema, hydrogel-acne, infection, prevention in which pro-patch and spray patch is the market focused product. The company is attaining lucrative growth through several strategic initiatives.

For instance,

  • In April, Phagelux, Inc. announced that the company has entered into multiple commercial collaborations such as European sales, marketing, and product development collaboration with DCM for its AgriPhage line of biopesticides, among others. This has helped the company to fully explore and develop next-generation bacteriophages

The company has a presence across the Americas, Europe, Asia-Pacific.